Relapse incidence (left side) and event-free survival (right side) by age at diagnosis of 100 children with juvenile myelomonocytic leukemia (JMML) transplanted after a conditioning regimen including busulfan, cyclophosphamide and melphalan from an matched related (n = 48) or a matched unrelated (n = 52) donor.¹³